NGR-hTNF
This is a study in second line treatment for patients with advanced mesothelioma who have been pre-treated with no more than one pemetrexed (aka Alimta) based chemotherapy regime. It's currently recruiting in Manchester, Maidstone, Leicester, Northwood, Glasgow, Sutton and London.
The trial involves a weekly 60 minute IV infusion of the agent, either on its own or in combination with another agent. It continues until confirmed evidence of disease progression, or unacceptable toxicity occurs.
ADI-PEG 20
This trial is currently recruiting in Cambridge, Hull, London, Manchester and Southampton, including patients who have been previously treated with a platinum-based chemotherapy regime. To be eligible to take part, you need to be tested to see if you are "ASS-negative".
The trial drug is given weekly for six months.
For more information on both trials search via the UK Clinical Trial Gateway website.
